Stand Up To Cancer teamed up with Eli Lilly and Company and SU2C ambassador Greg Kinnear for a new colorectal cancer PSA.
The radio and print PSA is designed to raise awareness about the importance of patient empowerment and knowledge of personalized colorectal cancer treatments matched to the genetic and molecular makeup of the patient’s tumor. March is Colon Rectal Cancer Awareness month.
According to the Centers for Disease Control and Prevention (CDC), colorectal cancer (cancer of the colon or rectum) is the second leading cancer killer of men and women combined, and the third most common form of cancer in the United States.
In 2016, about 135,000 people in the U.S. will be diagnosed with colorectal cancer, and it will claim the lives of almost 50,000. The PSA encourages colorectal cancer patients to visit standup2cancer.org/colorectalcancer to learn more about how testing for the genetic and molecular characteristics of their own individual colorectal cancer, may help patients with their doctors select safer, more effective treatment.
“I’m proud to help Stand Up To Cancer and their supporter Lilly Oncology raise awareness for colorectal cancer,” said award-winning actor Kinnear. “Through this PSA campaign, we want people to realize they are their most powerful advocates. If diagnosed with colorectal cancer, it is important to ask questions, be informed and to know the makeup of your tumor to help you and your doctor decide on the best possible treatment.”
